Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 57852-57-0] Idarubicinhydrochloride

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-17381
Brand:	MCE
CAS:	57852-57-0

Overview

MDL	MFCD00897212
Molecular Weight	533.95
Molecular Formula	C26H28ClNO9
SMILES	OC(C(C(C1=CC=CC=C21)=O)=C3C2=O)=C4[C@H](C[C@@](C(C)=O)(O)CC4=C3O)O[C@@](O[C@@H](C)[C@H]5O)([H])C[C@@H]5N.Cl

For research use only. We do not sell to patients.

8 Publications Citing Use of MCE

[1]Nucleic Acids Res. 2018 Apr 20;46(7):3284-3297.
[2]Cancer Lett. 2019 Oct 1;461:31-43.
[3]Anal Chem. 2022 Oct 4;94(39):13623-13630.
[4]J Virol. 2019 May 15;93(11):e02230-18.
[5]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
[6]Viruses. 2020 Jun 10;12(6):628.
[7]Exp Cell Res. 2020 Aug 1;393(1):112054.
[8]bioRxiv. 2023 Jan 13.

Summary

Idarubicin hydrochloride is an anthracycline antileukemic drug. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts .

IC50 & Target

Topoisomerase II

In Vitro

The IC ₅₀ of idarubicin is 3.3±0.4 ng/mL on MCF-7 monolayers and 7.9±1.1 ng/mL in multicellular spheroids ^[1] . Idarubicin has shown a greater cytotoxicity than daunorubicin or doxorubicin in various in vitro systems. This has been attributed to a better ability of idarubicin to induce the formation of topoisomerase II -mediated DNA breaks ^[2] .Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively ^[3] . Idarubicin produces a concentration-dependent reduction in cell growth, with an IC ₅₀ value of approximately 0.01 μM. Idarubicin produced a concentration-dependent inhibition of DNA synthesis ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00542971	M.D. Anderson Cancer Center\|Bayer	AML\|Acute Myeloid Leukemia\|Myelodysplastic Disorders	October 2007	Phase 1\|Phase 2
NCT01534702	Hannover Medical School\|Genzyme, a Sanofi Company	Acute Myeloid Leukemia	January 2012	Phase 1\|Phase 2
NCT01700413	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias\|Ministry of Health, Spain\|Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau	Di Novo Acute Myeloid Leukemia	October 2012	Phase 2
NCT00002532	Hannover Medical School\|National Cancer Institute (NCI)	Leukemia	January 1993	Phase 2
NCT01773408	Hoffmann-La Roche	Myelogenous Leukemia, Acute	February 2013	Phase 1
NCT00003639	Scotland and Newcastle Lymphoma Group\|National Cancer Institute (NCI)	Lymphoma	November 1993	Phase 3
NCT02632708	Institut de Recherches Internationales Servier\|Celgene Corporation\|Servier	Newly Diagnosed Acute Myeloid Leukemia (AML)\|Untreated AML\|AML Arising From Myelodysplastic Syndrome (MDS)\|AML Arising From Antecedent Hematologic Disorder (AHD)\|AML Arising After Exposure to Genotoxic Injury	December 31, 2015	Phase 1
NCT05518383	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Non-hodgkin Lymphoma,B Cell\|Burkitt Lymphoma\|Primary Mediastinal Lymphoma\|Primary CNS Lymphoma\|Diffuse Large B-cell Lymphoma	May 25, 2022	Phase 4
NCT01889407	Nanfang Hospital of Southern Medical University\|Pfizer	Acute Myeloid Leukemia	August 2013
NCT02703272	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Lymphoma, Non-Hodgkin	July 1, 2016	Phase 3
NCT01692197	M.D. Anderson Cancer Center\|Eisai Inc.	Leukemia	February 1, 2013	Phase 2
NCT01607645	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts	July 2012	Phase 2
NCT00199095	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia	February 1997	Phase 4
NCT04069208	Peking Union Medical College Hospital	Acute Myeloid Leukemia	September 3, 2019	Phase 2
NCT03553238	Nanfang Hospital of Southern Medical University	Leukemia, Acute\|Leukemia, T Cell\|Leukemia, Lymphoblastic	February 14, 2016	Phase 2\|Phase 3
NCT00006122	European Organisation for Research and Treatment of Cancer - EORTC	Leukemia	June 2000	Phase 2
NCT01305135	Groupe Francophone des Myelodysplasies	High Grade Myelodysplastic Syndrome Lesions	December 30, 2010	Phase 1\|Phase 2
NCT00016159	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia	November 2000	Phase 2
NCT00180128	Technische Universität Dresden	Leukemia, Promyelocytic, Acute	January 2000	Phase 4
NCT03727633	University Hospital, Montpellier\|Guerbet	Carcinoma, Hepatocellular	July 19, 2018	Phase 2
NCT03591510	Novartis Pharmaceuticals\|Novartis	FLT3-mutated Acute Myeloid Leukemia	March 13, 2019	Phase 2
NCT02115295	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Biphenotypic Leukemia\|Acute Myeloid Leukemia\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Blasts 10 Percent or More of Bone Marrow Nucleated Cells\|Blasts 10 Percent or More of Peripheral Blood White Cells\|de Novo Myelodysplastic Syndrome\|Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	May 19, 2014	Phase 2
NCT02848183	Samsung Medical Center	Pediatric Acute Myeloid Leukemia	January 2016	Phase 2
NCT00528450	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)\|Cephalon	Leukemia	September 2007	Phase 2
NCT05313958	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Third Affiliated Hospital, Sun Yat-Sen University\|Maternal and Child Health Hospital of Foshan\|The First Affiliated Hospital of Guangzhou Medical University\|Second Xiangya Hospital of Central South University\|Jiangxi Province Children´s Hospital\|Southern Medical University, China\|The First Affiliated Hospital of Nanchang University\|Guangzhou First People´s Hospital\|First Affiliated Hospital of Shantou University Medical College	Leukemia, Monocytic, Acute\|Pediatric AML	December 1, 2021	Phase 2\|Phase 3
NCT01990807	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Childhood Acute Lymphoblastic Leukemia\|Philadelphia Chromosome, Ph^1^, Absent\|B-cell Childhood Acute Lymphoblastic Leukemia	October 2012	Phase 4
NCT00002798	National Cancer Institute (NCI)	Childhood Acute Erythroleukemia (M6)\|Childhood Acute Megakaryocytic Leukemia (M7)\|Childhood Acute Monoblastic Leukemia (M5a)\|Childhood Acute Monocytic Leukemia (M5b)\|Childhood Acute Myeloblastic Leukemia With Maturation (M2)\|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)\|Childhood Acute Myelomonocytic Leukemia (M4)\|Childhood Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Refractory Anemia\|Refractory Anemia With Excess Blasts\|Refractory Anemia With Excess Blasts in Transformation\|Refractory Anemia With Ringed Sideroblasts\|Secondary Myelodysplastic Syndromes\|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	August 1996	Phase 3
NCT02779283	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia	January 13, 2016	Phase 1
NCT03214562	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	High Risk Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia	September 26, 2017	Phase 1\|Phase 2
NCT00002926	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	December 1996	Phase 3
NCT00505700	Massachusetts General Hospital\|Millennium Pharmaceuticals, Inc.	Leukemia	July 2003	Phase 1
NCT00210366	International Extranodal Lymphoma Study Group (IELSG)	Lymphoma, B-Cell	November 2004	Phase 2
NCT02905994	Massachusetts General Hospital\|Boehringer Ingelheim	AML	September 2016	Phase 1
NCT00198978	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia	January 2003	Phase 4
NCT03117751	St. Jude Children´s Research Hospital\|Incyte Corporation\|Amgen\|Servier	Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Lymphoma	March 29, 2017	Phase 2\|Phase 3
NCT00096148	National Cancer Institute (NCI)	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Childhood Acute Basophilic Leukemia\|Childhood Acute Eosinophilic Leukemia\|Childhood Acute Erythroleukemia (M6)\|Childhood Acute Megakaryocytic Leukemia (M7)\|Childhood Acute Monoblastic Leukemia (M5a)\|Childhood Acute Monocytic Leukemia (M5b)\|Childhood Acute Myeloblastic Leukemia With Maturation (M2)\|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)\|Childhood Acute Myelomonocytic Leukemia (M4)\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia\|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	October 2004	Phase 2
NCT01518556	Konkuk University Medical Center\|Chung-Ang University Hosptial, Chung-Ang University College of Medicine\|Seoul National University Hospital\|Ewha Womans University\|Samsung Medical Center\|Chonbuk National University Hospital\|Pusan National University Hospital\|Hanyang University Seoul Hospital\|Soon Chun Hyang University	Leukemia, Myeloid, Acute	July 2011	Phase 1\|Phase 2
NCT02635074	Steven E. Coutre\|National Cancer Institute (NCI)\|Stanford University	Recurrent Adult Acute Myeloid Leukemia	November 2016	Phase 1
NCT01831232	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Refractory Anemia With Excess Blasts\|Untreated Adult Acute Myeloid Leukemia	May 2013	Not Applicable
NCT00382954	University of Kentucky\|National Institutes of Health (NIH)	Acute Myelogenous Leukemia	February 2004	Phase 1
NCT02096055	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Untreated Adult Acute Myeloid Leukemia	April 4, 2014	Phase 2
NCT00146120	University of Ulm	Acute Myeloid Leukemia	May 1998	Phase 3
NCT01025154	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Acute Myeloid Leukemia	January 2010	Phase 2
NCT02306291	GlycoMimetics Incorporated	Leukemia, Myeloid, Acute	March 2015	Phase 1\|Phase 2
NCT00464217	PETHEMA Foundation	Acute Myeloblastic Leukaemia	October 1998	Phase 4
NCT00002719	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia\|Neutropenia	December 1995	Phase 3
NCT04190550	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome	July 29, 2020	Phase 1
NCT00002701	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto\|National Cancer Institute (NCI)	Leukemia	October 1995	Phase 3
NCT00002771	German CML Study Group\|National Cancer Institute (NCI)	Leukemia	January 1995	Phase 3
NCT04112589	PETHEMA Foundation\|Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company\|Syntax for Science, S.L	Acute Myeloid Leukemia	December 26, 2019	Phase 1\|Phase 2
NCT00002812	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	September 1996	Phase 3
NCT00003405	Rush University Medical Center\|National Cancer Institute (NCI)	Leukemia	April 1998	Phase 2
NCT00004905	Loyola University\|National Cancer Institute (NCI)	Leukemia	October 1999	Phase 2
NCT00093483	Roswell Park Cancer Institute\|National Cancer Institute (NCI)	Leukemia	April 2002	Phase 1
NCT01958996	Poitiers University Hospital	High Grade Lymphomas CD20 Positive	January 2009	Phase 1\|Phase 2
NCT00002609	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia	August 1994	Phase 2
NCT03926624	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	November 22, 2019	Phase 3
NCT02049801	Bruno C. Medeiros\|National Cancer Institute (NCI)\|Stanford University	Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	December 2014	Phase 1
NCT02527174	University of Alberta	Leukemia, Myeloid, Acute\|Leukemia, Monocytic, Acute\|Leukemia, Myelomonocytic, Acute\|Leukemia, Erythroblastic, Acute\|Leukemia, Megakaryoblastic, Acute	November 2016	Phase 1
NCT02339740	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Promyelocytic Leukemia With PML-RARA	June 29, 2015	Phase 3
NCT00077116	European Organisation for Research and Treatment of Cancer - EORTC	Leukemia\|Myelodysplastic Syndromes	November 2003	Phase 2
NCT00023920	National Cancer Institute (NCI)	Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive	July 2001	Phase 2
NCT04107727	PETHEMA Foundation\|Dynamic Science S.L.\|Daiichi Sankyo, Inc.	Acute Myeloid Leukemia	September 5, 2019	Phase 2
NCT01040559	Centre Hospitalier Universitaire Dijon	Carcinoma, Hepatocellular	December 2009	Phase 1
NCT00002945	Roswell Park Cancer Institute	Leukemia	December 1996	Phase 3
NCT00067028	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Chronic Myeloid Leukemia	December 2003	Phase 2
NCT01154439	Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	October 2010	Phase 1
NCT00209833	Hannover Medical School\|University of Ulm\|Johann Wolfgang Goethe University Hospital\|University Hospital Freiburg\|University Hospital Augsburg\|Humboldt-Universität zu Berlin\|Universitätsklinikum Hamburg-Eppendorf\|University Hospital, Ghent\|Medizinische Universitätsklinik Tübingen\|Klinikum Hanover-Siloah Hospital\|Ev. Krankenhaus Essen-Werden\|Klinikum Wuppertal GmbH	De Novo Akute Myeloid Leukemia (AML)\|Secondary Acute Myeloid Leukemia (AML)\|Refractory Anemia With Excess of Blasts in Transformation	January 1999	Phase 2\|Phase 3
NCT02626338	Arog Pharmaceuticals, Inc.	Relapsed+Refractory Acute Myeloid Leukemia (AML)	February 2016	Phase 1\|Phase 2
NCT02416388	University Hospital, Angers	Acute Myeloid Leukemia (AML)	January 2015	Phase 2\|Phase 3
NCT00003602	Riverside Haematology Group\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	March 1998	Phase 3
NCT01132586	National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1\|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL\|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA\|Alkylating Agent-Related Acute Myeloid Leukemia\|de Novo Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndrome\|Untreated Adult Acute Myeloid Leukemia	May 2010	Phase 1
NCT01876953	City of Hope Medical Center\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Recurrent Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	September 13, 2013	Phase 1\|Phase 2
NCT04687098	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias	Leukemia, Myeloid, Acute	February 1, 2012	Not Applicable
NCT02236013	Astellas Pharma Global Development, Inc.\|Astellas Pharma Inc	Acute Myeloid Leukemia	January 7, 2015	Phase 1
NCT01289457	M.D. Anderson Cancer Center	Leukemia	February 2, 2011	Phase 1\|Phase 2
NCT00967057	Children´s Cancer and Leukaemia Group\|National Cancer Institute (NCI)	Leukemia	October 2002	Phase 3
NCT02881086	Goethe University	Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma	August 2016	Phase 3
NCT00002517	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	March 1993	Phase 3
NCT00482833	Gruppo Italiano Malattie EMatologiche dell´Adulto\|Study Alliance Leukemia (SAL) Group	Leukemia	August 2007	Phase 3
NCT01039363	Samsung Medical Center	Acute Myeloid Leukemia		Phase 2
NCT00199147	Johann Wolfgang Goethe University Hospital	Acute Myeloid Leukemia	January 2000	Phase 4
NCT00317408	European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma\|National Cancer Institute (NCI)	Lymphoma	April 2004	Not Applicable
NCT04047641	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Blasts 20 Percent or More of Bone Marrow Nucleated Cells\|High Risk Myelodysplastic Syndrome\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent High Risk Myelodysplastic Syndrome\|Refractory Acute Myeloid Leukemia\|Refractory High Risk Myelodysplastic Syndrome	October 22, 2019	Phase 1\|Phase 2
NCT01435343	PETHEMA Foundation	Acute Myeloblastic Leukemia	July 2012	Phase 1\|Phase 2
NCT00331513	National Cancer Institute (NCI)	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Promyelocytic Leukemia (M3)\|Blastic Phase Chronic Myelogenous Leukemia\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	March 2006	Phase 1
NCT03349957	University Hospital, Montpellier	Hepatocellular Carcinoma (HCC)	December 1, 2017
NCT03589729	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Blasts 10 Percent or More of Bone Marrow Nucleated Cells\|High Risk Myelodysplastic Syndrome\|Myeloid Sarcoma\|Myeloproliferative Neoplasm\|Philadelphia Chromosome Positive	September 19, 2018	Phase 2
NCT02249091	GSO Global Clinical Research BV\|Karyopharm Therapeutics Inc	Acute Myeloid Leukemia (Relapsed+Refractory)	September 2014	Phase 2
NCT00002565	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Lymphoma	May 25, 1994	Phase 3
NCT01035502	Clavis Pharma\|Theradex\|Syneos Health	Acute Myeloid Leukemia	December 2009	Phase 2
NCT02688140	Technische Universität Dresden\|Gruppo Italiano Malattie EMatologiche dell´Adulto\|Groupe Francophone des Myelodysplasies\|HOVON - Dutch Haemato-Oncology Association\|Programa para el Tratamiento de Hemopatías Malignas\|German Federal Ministry of Education and Research\|Teva Pharmaceuticals Europe	Acute Promyelocytic Leukemia	June 2016	Phase 3
NCT02873338	Chimerix	Acute Myeloid Leukemia	August 2016	Phase 2
NCT04214249	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	June 1, 2020	Phase 2
NCT00666588	National Cancer Institute (NCI)	Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Childhood Acute Basophilic Leukemia\|Childhood Acute Eosinophilic Leukemia\|Childhood Acute Erythroleukemia (M6)\|Childhood Acute Megakaryocytic Leukemia (M7)\|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)\|Childhood Acute Monoblastic Leukemia (M5a)\|Childhood Acute Monocytic Leukemia (M5b)\|Childhood Acute Myeloblastic Leukemia With Maturation (M2)\|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)\|Childhood Acute Myelomonocytic Leukemia (M4)\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia	April 2008	Phase 2
NCT01540812	PETHEMA Foundation	Acute Lymphoblastic Leukemia	February 2012
NCT00003783	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	March 1999	Phase 2
NCT00003729	European Organisation for Research and Treatment of Cancer - EORTC	Leukemia	December 1998	Phase 2
NCT02440568	University of Illinois at Chicago\|Teva Pharmaceuticals USA	Acute Myeloid Leukemia	June 5, 2015	Phase 1\|Phase 2
NCT00198991	Goethe University\|Deutsche Krebshilfe e.V., Bonn (Germany)\|German Federal Ministry of Education and Research	Adult Acute Lymphocytic Leukemia	April 2003	Phase 4
NCT02029950	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Chronic Myelomonocytic Leukemia-2\|High Risk Myelodysplastic Syndrome\|Myeloproliferative Neoplasm	December 16, 2013	Phase 1
NCT00866918	Children´s Oncology Group\|National Cancer Institute (NCI)	Childhood Acute Promyelocytic Leukemia With PML-RARA\|Myeloid Neoplasm	March 9, 2009	Phase 3
NCT00002800	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Neutropenia	July 1996	Phase 2
NCT02652871	M.D. Anderson Cancer Center\|Eli Lilly and Company\|High Impact Clinical Research Support Program	Leukemia	May 9, 2016	Phase 1
NCT00002835	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Lymphoma	October 30, 1995	Phase 3
NCT05260528	Centre Hospitalier Universitaire de Nice\|Jazz Pharmaceuticals\|Acute Leukemia French Association	Acute Myeloid Leukemia	April 2022	Phase 2
NCT01180322	University of Ulm	Acute Myeloid Leukemia (AML)	November 2010	Phase 2
NCT00074737	Eleos, Inc.	Acute Myelogenous Leukemia	April 2004	Phase 2
NCT00199186	Johann Wolfgang Goethe University Hospital	Philadelphia Positive Acute Lymphoblastic Leukemia\|Lymphoid Blastic Phase of Chronic Myeloid Leukemia	March 2002	Phase 2
NCT03564704	Nanfang Hospital of Southern Medical University	Leukemia\|Leukemia, Acute\|Adult Lymphoblastic Lymphoma\|Leukemia, Lymphoblastic\|Leukemia, T Cell\|Adult Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma\|Lymphoblastic Leukemia	February 14, 2016	Phase 2\|Phase 3
NCT00002989	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes	March 1997	Phase 3
NCT00151242	University of Ulm	Acute Myeloid Leukemia	July 2004	Phase 2\|Phase 3
NCT03226418	University of Nebraska\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia	July 7, 2017	Phase 2
NCT00003268	Sidney Kimmel Cancer Center at Thomas Jefferson University\|National Cancer Institute (NCI)	Drug+Agent Toxicity by Tissue+Organ\|Leukemia	January 1998	Phase 1
NCT04216771	Fujian Medical University	AML in Remission	January 2020	Phase 2\|Phase 3
NCT00107523	Fred Hutchinson Cancer Center	Leukemia	January 2005	Phase 1
NCT00199056	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia	October 1999	Phase 4
NCT03444649	University Hospital Inselspital, Berne	AML	September 2018	Phase 1
NCT00831766	H. Lee Moffitt Cancer Center and Research Institute\|Celgene	Myelodysplastic Syndrome\|Acute Myeloid Leukemia	June 25, 2009	Phase 1\|Phase 2
NCT02464657	M.D. Anderson Cancer Center\|Bristol-Myers Squibb	Leukemia\|Acute Myeloid Leukemia\|Myelodysplastic Syndrome	July 2015	Phase 1\|Phase 2
NCT00025402	III. Medizinische Klinik Mannheim\|National Cancer Institute (NCI)	Leukemia	July 1997	Phase 3
NCT01141725	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|de Novo Myelodysplastic Syndromes\|Myelodysplastic Syndrome With Isolated Del(5q)\|Untreated Adult Acute Myeloid Leukemia	September 2010	Phase 1\|Phase 2
NCT04801797	Massachusetts General Hospital\|AbbVie	Acute Myeloid Leukemia	May 20, 2021	Phase 2
NCT00801489	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11\|Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11\|Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1\|de Novo Myelodysplastic Syndrome\|High Risk Myelodysplastic Syndrome\|Inv(16)\|Myelodysplastic Syndrome With Excess Blasts\|t(16;16)\|t(8;21)\|Untreated Adult Acute Myeloid Leukemia	April 4, 2007	Phase 2
NCT02560025	Massachusetts General Hospital\|Takeda	Acute Myeloid Leukemia	December 2015	Phase 2
NCT00656617	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	April 2008	Phase 2
NCT03250338	Arog Pharmaceuticals, Inc.	Relapsed+Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	June 5, 2018	Phase 3
NCT02400281	Arog Pharmaceuticals, Inc.	Acute Myeloid Leukemia	September 2015	Phase 1\|Phase 2
NCT02046122	Duke University	Acute Myeloid Leukemia\|Myelodysplastic Syndrome	July 2014	Phase 1\|Phase 2
NCT00002658	Medical Research Council\|National Cancer Institute (NCI)	Leukemia\|Neutropenia	January 1994	Phase 3
NCT02185768	Federation Francophone de Cancerologie Digestive	Liver Cancer	January 2015	Phase 2
NCT02144675	Rutgers, The State University of New Jersey\|Rutgers Cancer Institute of New Jersey\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	January 2009	Phase 2
NCT00002833	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Graft Versus Host Disease\|Leukemia\|Myelodysplastic Syndromes	October 1994	Phase 2
NCT05177731	Chen Suning\|The First Affiliated Hospital of Soochow University	AML, Adult\|Chemotherapy Effect	March 1, 2022	Phase 3
NCT00838240	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia\|Myelodysplastic Syndromes	November 2008	Phase 1\|Phase 2
NCT02680951	Emory University	Acute Myeloid Leukemia	December 2015	Phase 1
NCT01779843	Massachusetts General Hospital	Acute Myelogenous Leukemia	April 2013	Phase 1
NCT01822015	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Untreated Adult Acute Myeloid Leukemia	March 15, 2013	Early Phase 1
NCT00528398	City of Hope Medical Center\|National Cancer Institute (NCI)	Leukemia	September 1994	Phase 2
NCT01794702	M.D. Anderson Cancer Center	Leukemia	February 20, 2013	Phase 1\|Phase 2
NCT00003758	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia	December 1998	Phase 2
NCT00413166	M.D. Anderson Cancer Center	Acute Promyelocytic Leukemia	December 2006	Phase 2
NCT00002761	Columbia University	Leukemia	February 1996	Phase 1\|Phase 2
NCT00363025	Acute Leukemia French Association\|Assistance Publique - Hôpitaux de Paris	Acute Myeloid Leukemia	November 1999	Phase 3
NCT03330821	University of Southern California\|National Cancer Institute (NCI)	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Therapy-Related Acute Myeloid Leukemia	April 18, 2018	Phase 1\|Phase 2
NCT00096122	National Cancer Institute (NCI)	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Childhood Myelodysplastic Syndromes\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Refractory Anemia With Excess Blasts\|Refractory Anemia With Excess Blasts in Transformation\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes\|Untreated Adult Acute Myeloid Leukemia	September 2004	Phase 1\|Phase 2
NCT05404516	Nanfang Hospital of Southern Medical University\|Guangzhou First People´s Hospital\|Guangzhou Panyu Central Hospital\|Institute of Hematology & Blood Diseases Hospital\|Peking University People´s Hospital\|Shenzhen Hospital of Southern Medical University\|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Core Binding Factor Acute Myeloid Leukemia	January 1, 2020	Phase 2
NCT02835729	NewLink Genetics Corporation\|Lumos Pharma	Acute Myeloid Leukemia	July 2016	Phase 1
NCT05280444	Zhongda Hospital	Hepatocellular Carcinoma	May 1, 2022	Phase 2\|Phase 3
NCT05053425	LanZhou University	Acute Myeloid Leukemia	October 20, 2021	Not Applicable
NCT02441803	M.D. Anderson Cancer Center	Leukemia	September 14, 2015	Phase 2
NCT02937662	Institute of Hematology & Blood Diseases Hospital	Acute Myeloid Leukemia	October 2016	Phase 2
NCT00878722	Onxeo	Acute Myeloid Leukemia	August 2007	Phase 1\|Phase 2
NCT00006367	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders	May 2000	Phase 2
NCT00534469	City of Hope Medical Center\|National Cancer Institute (NCI)	Leukemia	February 8, 2000	Phase 2
NCT00002868	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Leukemia	January 1996	Phase 3
NCT03194932	St. Jude Children´s Research Hospital\|Gateway for Cancer Research	Acute Myeloid Leukemia	July 11, 2017	Phase 1
NCT03661515	PETHEMA Foundation	Acute Myeloid Leukemia	July 17, 2018	Phase 1
NCT00151255	University of Ulm	Acute Myeloid Leukemia	June 2004	Phase 3
NCT01802333	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	February 12, 2013	Phase 3
NCT03860844	Sanofi	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia	August 6, 2019	Phase 2
NCT02283177	Arog Pharmaceuticals, Inc.	Newly Diagnosed AML With FLT3 Activating Mutations	January 2015	Phase 2
NCT00003178	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	March 1998	Phase 2
NCT02020161	PETHEMA Foundation	APL	June 2012	Phase 4
NCT02310321	Astellas Pharma Inc	Acute Myeloid Leukemia\|FLT3-mutated Acute Myeloid Leukemia	February 26, 2015	Phase 1\|Phase 2
NCT02135874	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Acute Leukemia of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Mixed Phenotype Acute Leukemia\|Mixed Phenotype Acute Leukemia, B+Myeloid, Not Otherwise Specified\|Mixed Phenotype Acute Leukemia, T+Myeloid, Not Otherwise Specified\|Recurrent Mixed Phenotype Acute Leukemia	October 27, 2014	Phase 2
NCT03164057	St. Jude Children´s Research Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	June 15, 2017	Phase 2
NCT00124813	University Hospital, Bonn	Multiple Myeloma	August 2002	Phase 2
NCT00003603	Riverside Haematology Group\|National Cancer Institute (NCI)	Multiple Myeloma and Plasma Cell Neoplasm	March 1998	Phase 3
NCT02013648	University of Ulm	Acute Myeloid Leukemia (AML)	July 2014	Phase 3
NCT00002549	European Organisation for Research and Treatment of Cancer - EORTC\|National Cancer Institute (NCI)	Leukemia	November 1993	Phase 3
NCT00620321	Eli Lilly and Company	Acute Myeloid Leukemia	March 2008	Phase 2
NCT02834390	Daiichi Sankyo Co., Ltd.\|Daiichi Sankyo, Inc.	Acute Myeloid Leukemia	August 12, 2016	Phase 1
NCT04778397	Gilead Sciences	Acute Myeloid Leukemia	July 1, 2021	Phase 3
NCT00487448	PETHEMA Foundation	Myelodysplastic Syndrome\|Acute Myeloblastic Leukemia	July 1998	Phase 4
NCT00458848	Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	October 2004	Phase 2
NCT00004878	Jonsson Comprehensive Cancer Center	Graft Versus Host Disease\|Leukemia		Phase 2
NCT05053386	Zhejiang Cancer Hospital	Hepatocellular Carcinoma	October 2021	Not Applicable
NCT00840177	Southwest Oncology Group\|National Cancer Institute (NCI)	Leukemia	August 2009	Phase 2
NCT00006232	West of Scotland Lymphoma Group\|National Cancer Institute (NCI)	Multiple Myeloma and Plasma Cell Neoplasm	October 1996	Phase 3
NCT00052299	European Organisation for Research and Treatment of Cancer - EORTC\|Gruppo Italiano Malattie EMatologiche dell´Adulto	Leukemia	September 2002	Phase 3
NCT00005823	Leukemia Research Fund\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	December 1998	Phase 3
NCT00469859	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	June 2007	Phase 1\|Phase 2
NCT03390387	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Childhood Acute Lymphoblastic Leukemia	November 2015	Not Applicable
NCT00422591	M.D. Anderson Cancer Center	Leukemia\|Acute Myeloid Leukemia\|AML	December 2006	Phase 2
NCT02277847	Guangdong Provincial People´s Hospital	Acute Myeloid Leukemia	March 2010	Phase 4
NCT01484171	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences	Acute Myeloid Leukemia	August 2011	Phase 3
NCT00002816	Children´s Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 1996	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL ( 156.06 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8728 mL	9.3642 mL	18.7283 mL
5 mM	0.3746 mL	1.8728 mL	3.7457 mL
10 mM	0.1873 mL	0.9364 mL	1.8728 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (3.90 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7.
[2] Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88.
[3] Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70.
[4] Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361-
[5] Kinnunen U, et al. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28(3):301-3.

Synonyms

5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, hydrochloride (1:1), (7S,9S)-

5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, hydrochloride, (7S-cis)-

5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, hydrochloride, (7S,9S)-

4-Demethoxydaunorubicin hydrochloride

Idarubicin hydrochloride

Idamycin

Zavedos

4-DMD HCl

NSC 256439

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart